IXICO plc AI Stock Analysis
Want to see GB:IXI full AI Analyst Report?
IXICO plc (IXI) AI Stock Analysis
IXICO plc
(LSE:IXI)
Strong earnings call momentum and solid technical uptrend are the primary drivers, tempered by weak profitability and negative valuation metrics despite balance sheet stability.
IXICO plc (IXI) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 27.92M
- Dividend Yield
- ―
- Average Volume (3M)
- 167.74K
- Price to Earnings (P/E)
- -6.5
- Beta (1Y)
- 0.33
- Revenue Growth
- 13.04%
- EPS Growth
- 15.88%
- Country
- UK
- Employees
- 79
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
IXICO plc Business Overview & Revenue Model
Company Description
IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and in...
How the Company Makes Money
IXICO makes money by providing contracted services to life sciences customers (such as pharmaceutical and biotechnology companies and, where applicable, clinical research organizations) involved in clinical development programs. Revenue is primarily...
IXICO plc Earnings Call Summary
The call conveyed solid operational progress and strong commercial momentum: double-digit revenue growth (23% in H1), a record GBP 18.1m order book providing 95% coverage of FY26 guidance, improved gross margin (53%), a narrowed EBITDA loss (GBP 0.5m), a successful GBP 10m capital raise and a strategic Medidata partnership that supports productization and scaling. Offsetting these positives are continuing near-term losses, timing risk for TechBio-derived recurring revenue due to productization and regulatory timelines, some exposure to trial descopes/cancellations and the need to convert an increasingly promising pipeline into contracted revenue in large indications like Alzheimer’s and Parkinson’s. Overall, the momentum and balance sheet reinforcement from the capital raise materially outweigh the near-term investment-driven drawbacks, but investors should note the multi-year horizon to realize TechBio recurring revenue and the stated 2029 target for sustained profitability.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company reiterated full‑year revenue guidance of GBP 7.5m (15% growth target) after a strong H1: revenues of GBP 3.9m (+23% YoY), 53% gross margin and an EBITDA loss narrowed to GBP 0.5m; management said the record order book of GBP 18.1m (up 31% since year‑end and 38% vs H1 2025) provides ~95% visibility of this year’s guidance. Over the last 12 months IXICO recognized GBP 7.2m of revenue, signed GBP 12.6m of new contracts (book‑to‑bill 1.75) and now has its largest project at 19% of order book; cash at half‑year was GBP 1.7m, augmented by GBP 9.4m net raise to GBP 10.8m at end‑April, with net assets GBP 10.7m (long‑term assets ~GBP 8m, working capital ~GBP 3.3m, lease liabilities ~GBP 0.5m). Management expects sustainable profitability and positive cash flow by 2029, will keep capex at c. GBP 300k per half (plus recent ~GBP 100k IT and ~GBP 100k refurb), aims to productize 2–3 TechBio products this year and targets FDA/software‑as‑medical‑device regulatory work on a 18–24 month horizon.
IXICO plc Financial Statement Overview
Summary
Strong balance sheet with minimal debt and solid equity base provides stability, but persistent net losses, negative margins, and cash burn constrain the score.
Income Statement
35NegativeBalance Sheet
75PositiveCash Flow
40Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.28M | 6.53M | 5.77M | 6.67M | 8.64M | 9.19M |
| Gross Profit | 3.51M | 2.91M | 2.71M | 3.27M | 4.77M | 5.53M |
| EBITDA | -2.33M | -2.02M | -1.68M | -707.00K | 1.55M | 1.73M |
| Net Income | -1.82M | -1.65M | -2.00M | -1.18M | 1.03M | 1.51M |
Balance Sheet | ||||||
| Total Assets | 12.99M | 13.84M | 11.19M | 12.99M | 14.65M | 14.26M |
| Cash, Cash Equivalents and Short-Term Investments | 1.68M | 3.54M | 1.79M | 4.03M | 5.77M | 6.68M |
| Total Debt | 559.00K | 179.00K | 314.00K | 387.00K | 516.00K | 597.00K |
| Total Liabilities | 2.27M | 2.10M | 1.72M | 1.56M | 2.16M | 2.78M |
| Stockholders Equity | 10.72M | 11.74M | 9.46M | 11.43M | 12.49M | 11.48M |
Cash Flow | ||||||
| Free Cash Flow | -2.17M | -934.00K | -2.20M | -1.66M | -815.00K | -1.54M |
| Operating Cash Flow | -2.02M | -883.00K | -1.73M | 302.00K | 1.43M | 614.00K |
| Investing Cash Flow | -1.11M | -870.00K | -377.00K | -1.86M | -2.25M | -2.15M |
| Financing Cash Flow | -202.00K | 3.50M | -134.00K | -156.00K | -114.00K | 270.00K |
IXICO plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Positive. The current price of 12.75 is above the 20-day moving average (MA) of 11.95, above the 50-day MA of 9.34, and above the 200-day MA of 8.38, indicating a bullish trend. The MACD of 1.25 indicates Positive momentum. The RSI at 63.01 is Neutral, neither overbought nor oversold. The STOCH value of 20.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:IXI.
IXICO plc Peers Comparison
Overall Rating
- GB:IXI63Neutral
GB:HVO49Neutral
GB:APTA46Neutral
GB:PYC41.5Neutral
GB:AVCT40Underperform
GB:OBD40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:IXI | 63Neutral | GBP 27.92M | -6.50 | -16.18% | ― | 13.04% | 15.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:HVO | 49Neutral | GBP 34.76M | -2.81 | -35.13% | 3.96% | -24.24% | -329.49% |
| GB:APTA | 46Neutral | GBP 12.66M | -12.17 | -46.61% | ― | 28.35% | 57.14% |
| GB:PYC | 42Neutral | GBP 1.99M | -2.13 | -152.03% | ― | 20.05% | -11.11% |
| GB:AVCT | 40Underperform | GBP 287.20M | -6.47 | -1293.07% | ― | ― | ― |
| GB:OBD | 40Underperform | GBP 15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:IXI | IXICO plc | 12.75 | 1.50 | 13.33% | |
| GB:AVCT | Avacta Group plc | 59.00 | -22.00 | -27.16% | |
| GB:OBD | Oxford BioDynamics | 0.12 | -0.17 | -58.93% | |
| GB:PYC | Physiomics plc | 0.42 | 0.01 | 1.19% | |
| GB:HVO | Open Orphan Plc | 5.05 | -1.25 | -19.84% | |
| GB:APTA | Aptamer Group Plc | 0.36 | -0.57 | -60.75% |
IXICO plc Corporate Events
IXICO secures £1.5m Alzheimer’s imaging and biomarker contracts after strong FY26
PositiveIXICO has announced two Alzheimer’s‑focused contracts worth a combined £1.5 million, underscoring the commercial traction of its IXI neuroimaging platform across a widening customer base. The deal news comes on the heels of a trading update showing 2...
IXICO beats revenue guidance as neuroimaging demand accelerates
PositiveIXICO plc expects revenues of £8.3 million for the year to 30 September 2026, representing 28% growth on 2025 and surpassing its recently upgraded guidance after a late surge in analysis orders. The group’s order book has risen to £16.0 million, enha...
IXICO beats guidance with 28% revenue growth and strengthened order book
PositiveIXICO plc expects revenue of £8.3 million for the year to 30 September 2026, a 28% increase on 2025 and ahead of upgraded guidance, driven by a late surge in analysis orders. The neuroscience-focused imaging specialist has grown its year-end order bo...
IXICO Showcases Neuromelanin MRI Advances for Parkinson’s Disease at European Radiology Meeting
PositiveIXICO plc has unveiled new research at the European Society for Magnetic Resonance in Medicine & Biology conference comparing two neuromelanin-sensitive MRI techniques for visualising the substantia nigra, a key brain region in Parkinson’s disease. B...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 03, 2026